|
|
Post by mnholdem on Oct 9, 2015 8:30:54 GMT -5
I wonder how many shareholders are open-minded to the idea that Sanofi learned a LOT from the Exubera rollout and that they are doing this right by not doing what Pfizer did to screw it up. In many analysts' opinion who have written about the failure, Pfizer launched their multi-$million DTC before bothering to adequately educate physicians and insurance companies. Initial demand was high, but the doctors were confused by the unit conversion and complicated device. As far as the insurance companies, the cost of Exubera with its "bong" inhaler was considerably higher than Afrezza, and their API had absolutely no known PK/PD benefit over RAA insulin.
As much as I hate the imposed silence (as does everyone) the scant information that has been disclosed by Matt, Hakan and Al has informed shareholders that Sanofi is working on areas which history shows that Pfizer failed to develop in their product launch.
Until I begin seeing insurance company tier placement, I don't expect to see a massive DTC. Until then, the jury is still out on Sanofi as far as I'm concerned.
Good fortune all.
|
|
|
|
Post by kdaddyfresh2000 on Oct 9, 2015 8:35:28 GMT -5
You are exactly right. There seems to be some after the fact analysis that SNY and MNKD had planned this 'controlled marketing plan' all along, but Matt's negative comments clearly indicates that was never true. The marketing has been a debacle and frankly I have no faith that SNY and MNKD will suddenly get it right. The best he could come up with was there are 'rumors' about TV ads. At this point, I wouldn't be surprised to see either MNKD or SBY abandon the partnership in January. Recently, I googled Exubera DTC marketing and found that they faced many of the exact same issues that Afrezza has, such as the lung test issues, black box warnings and insurance coverage. It seems to me that SNY learned nothing from Pfizer's previous failure. Of course, the primary differences are the size of the delivery device,less hypos, and social media(which really wasn't around in 2007). In fact, as bad as the script numbers are, where the hell would we be if twitter wasn't around. For what it's worth, there is a girl on Twitter named Melissa (@go2sleepjj) who claimed she works at SNY marketing and, based on previous posts, *seems* to be true. Who knows and if so, why she felt free to post, but I think she told the truth. Anyway, she twittered that no one wanted to work marketing for Afrezza at SNY in a Twitter 3 days ago. Intrigued, I tweeted back asking how she knows and why. She said she worked there and that the DTC was botched, thus SNY is trying to fix it with someone new doing it. She said if that new person screws up this new DTC, then it would be a negative "career changer," hence why no one wants to do it. She said SNY "was on it,"' though. If true, the bad is that SNY botched the DTC. Duh. The good is, is that SNY knows about it and is working to fix it. Anyone see that post from SA by mrcoleslaw: For what it's worth... "Sanofi rep visited w/ me this week - said Afrezza will now be marketed by people other than Sanofi reps. I asked about NRx data - although the rep didn't name numbers, the rep's facial expression said it all - and that the biggest barrier for people writing Afrezza was the PFTs that have to be performed before prescribing - this was a larger issue than most had believed it would be. Long-term will Afrezza do well? Likely, if it's affordable. I wanted to use it in a smoker who had COPD but this condition is contraindicated w/ Afrezza u" and "Toujeo was 90% the topic of conversation, followed by Apidra at 7.5% and Afrezza at 2.5%. One month the rep is touting the multiple benefits of Afrezza, the next month it's as though the medicine no longer existed. " Again, assuming this post is true, THIS situation on the ground concerns me. Are we getting the "oh by the way" sales pitch and the Junior Varsity Sales Team?!? I called and left a message with Matt asking about contract sales teams and the SNY commitment. No callback yet. And if we have a 50/50 Joint Advisory Committtee, why are we getting the scraps from the table (and why doesn't Matt know about commercials for TV, for that matter?!? Rumors of a commercial? Really?!). From what I understand from the Aug 14 CC, the contract did not require minimal sales effort numbers by SNY per standard biz practice and instead they went with the JAC. How's that working out for us?! Please no back and forth on "soft-bashing" blah blah blah. This stock is testing my patience and the criticisms IMO are very warranted. I am looking for constructive comments. |
|
|
|
Post by kdaddyfresh2000 on Oct 9, 2015 8:45:03 GMT -5
You are exactly right. There seems to be some after the fact analysis that SNY and MNKD had planned this 'controlled marketing plan' all along, but Matt's negative comments clearly indicates that was never true. The marketing has been a debacle and frankly I have no faith that SNY and MNKD will suddenly get it right. The best he could come up with was there are 'rumors' about TV ads. At this point, I wouldn't be surprised to see either MNKD or SBY abandon the partnership in January. Recently, I googled Exubera DTC marketing and found that they faced many of the exact same issues that Afrezza has, such as the lung test issues, black box warnings and insurance coverage. It seems to me that SNY learned nothing from Pfizer's previous failure. Of course, the primary differences are the size of the delivery device,less hypos, and social media(which really wasn't around in 2007). In fact, as bad as the script numbers are, where the hell would we be if twitter wasn't around. For what it's worth, there is a girl on Twitter named Melissa (@go2sleepjj) who claimed she works at SNY marketing and, based on previous posts, *seems* to be true. Who knows and if so, why she felt free to post, but I think she told the truth. Anyway, she twittered that no one wanted to work marketing for Afrezza at SNY in a Twitter 3 days ago. Intrigued, I tweeted back asking how she knows and why. She said she worked there and that the DTC was botched, thus SNY is trying to fix it with someone new doing it. She said if that new person screws up this new DTC, then it would be a negative "career changer," hence why no one wants to do it. She said SNY "was on it,"' though. If true, the bad is that SNY botched the DTC. Duh. The good is, is that SNY knows about it and is working to fix it. Anyone see that post from SA by mrcoleslaw: For what it's worth... "Sanofi rep visited w/ me this week - said Afrezza will now be marketed by people other than Sanofi reps. I asked about NRx data - although the rep didn't name numbers, the rep's facial expression said it all - and that the biggest barrier for people writing Afrezza was the PFTs that have to be performed before prescribing - this was a larger issue than most had believed it would be. Long-term will Afrezza do well? Likely, if it's affordable. I wanted to use it in a smoker who had COPD but this condition is contraindicated w/ Afrezza u" and "Toujeo was 90% the topic of conversation, followed by Apidra at 7.5% and Afrezza at 2.5%. One month the rep is touting the multiple benefits of Afrezza, the next month it's as though the medicine no longer existed. " Again, assuming this post is true, THIS situation on the ground concerns me. Are we getting the "oh by the way" sales pitch and the Junior Varsity Sales Team?!? I called and left a message with Matt asking about contract sales teams and the SNY commitment. No callback yet. And if we have a 50/50 Joint Advisory Committtee, why are we getting the scraps from the table (and why doesn't Matt know about commercials for TV, for that matter?!? Rumors of a commercial? Really?!). From what I understand from the Aug 14 CC, the contract did not require minimal sales effort numbers by SNY per standard biz practice and instead they went with the JAC. How's that working out for us?! Please no back and forth on "soft-bashing" blah blah blah. This stock is testing my patience and the criticisms IMO are very warranted. I am looking for constructive comments. Incidentally, I told Matt that no one knows about Afrezza despite the DTC. The decreasing scripts this week are another red flag. I would not be happy but could live with it if the product failed due to poor sales but had a fighting chance with good marketing and sales force support. In other words, it failed because the patients said "No" after a fair and accurate opportunity to use it was presented by their doctors. It is failing though because nobody knows about the drug! |
|
|
|
Post by vissertrades on Oct 9, 2015 9:04:04 GMT -5
We as investors own a piece of this company and entrust Management to act in good faith on our behalf. I believe it's called fiduciary duty. Management is payed to manage the company and products on our behalf and this includes their flagship product AFREZZA. BOD is in place to keep management in check but I get the feeling they are asleep and we are watching a train wreck unfold. With so much on the line management should be all over this with forward thinking plans of contingency and corrective action in place to mitigate risk. Seems they are reactive and not proactive. I've trusted for 5 years and am continually dissapointed. Time for the "A" team and BOD are the only ones that can make this change. An effective CEO would be a great start. Perhaps we craft a letter to BOD on behalf of shareholders?
|
|
|
|
Post by cretin11 on Oct 9, 2015 9:30:35 GMT -5
You hit the nail squarely on the head IMHO. Why would SNY an RHI producer invest millions of dollars on a product in which the insulin supply is dependent and potentially controlled by outside forces? Why would they conduct numerous studies to strengthen the label for a product in which their insulin is not used. SNY knows what they have in Afrezza, but they will only methodically move forward until they control the source of raw insulin. Imagine if they did ROW roll out and demand was significant. The supply is dependent upon a single AMPH plant. What if AMPH could not keep up with demand. What if AMPH were to be bought by a competitor. AMPH was always intended to be temporary. Remember the ownership change just prior to the MNKD/SNY agreement. Odd how that came about? When SNY gains approval as a secondary RHI source either by the FDA or EU filing, all hell breaks lose. They will then push the product to the wall, make the anticipated investment in MNKD. Furthermore, as they move into some markets it will be demanded of SNY that the raw insulin be manufactured in the host country. AMPH does not have that capability but SNY does.
I attended the conference with another member of this Board. The audio/video was f......'ed for 15 minutes as Wynnn employees tried to fix the issue. The room was sro and had twice as many people as two previous presentations that morning. I thought Matt did a fabulous job under the circumstances!!! - he was pressured by Room moderator to complete this presentation quickly- and obviously had good presentation prepared. There was much more information gathered after the conference - Matt is sharp and forthcoming - - bottom line - Hammer hits the nail on head above as well as Obamayoumama. Also - This is a highly manipulated/shorted stock - but 9M shares being returned in couple weeks. Also - Patryn's comments above are on target - I do not like where we are right now but I am content with this investment long term. We need SNY to execute and sell this product - bottom line. GWB/Joey - amazing what a good nights sleep can do. lol thanks chicagpete for the info. I'm understanding your take to be (in part) that when SNY gets approved to be the RHI source that should be a key occurence in a good way. Do we have any info to help us track/determine the progress of this? |
|
|
|
Post by babaoriley on Oct 9, 2015 9:38:03 GMT -5
Thoughts: For now, Al decides who the CEO is. Some very good posts on this thread. Heard presentation last night. Matt was very, very good under the circumstances. His voice was not unduly nervous, I've heard Matt's nervous voice and this was not it, he was merely rushing. He continues to improve as a speaker, and I thought this was his best job in that regard. His hands are tied on content. Presentations such as this are not where important stuff we don't already know about will be released, it's a canned presentation and nothing more. Chicagopete, nice job.  |
|
|
|
Post by rvc on Oct 9, 2015 9:44:53 GMT -5
If the comments from the sales rep are accurate, it is not surprising that the short interest in this stock is so massive.
|
|
|
|
Post by kball on Oct 9, 2015 9:44:48 GMT -5
Thoughts: For now, Al decides who the CEO is. Some very good posts on this thread. Heard presentation last night. Matt was very, very good under the circumstances. His voice was not unduly nervous, I've heard Matt's nervous voice and this was not it, he was merely rushing. He continues to improve as a speaker, and I thought this was his best job in that regard. His hands are tied on content. Presentations such as this are not where important stuff we don't already know about will be released, it's a canned presentation and nothing more.
Chicagopete, nice job. If i recall, petes been to other Mannkind conferences with boots on the ground reports. Greatly appreciated |
|
|
|
Post by mattmatt on Oct 9, 2015 9:48:58 GMT -5
If you have been in the stock more than a year, then the lack of transparency should have already been apparent before today. The management of MNKD is focused on creating long term value in MNKD which should ultimately reward shareholders, but could be to the detriment of those who demand constant updates as to progress. The truth is that the marketing and sales has been outsourced by MNKD to SNY and SNY is doing what it wants to in regards to that. I'm sure none of the shareholders of MNKD wanted the sales to be tepid at the moment, but SNY definitely has it's hands on the switch and there is nothing that MNKD management can do about it short of attempting to break the contract signed less than a year ago. We as shareholders of MNKD signed up for this arrangement because we knew the alternative was trying to market and sell Afrezza by ourselves which would have required far more capital outlay and expertise that no one at MNKD had. Matt could have given the best presentation in the world, and electrified the audience with his wit, vivacity, and charm. It would not change the sales picture one bit. Afrezza adoption needs to come from a well orchestrated marketing, education, and sales campaign and that is something that will take time. I have invested more than 10x what you have in MNKD and while I do not like the short term, I am content with my investment because I know that the odds of success are better than the odds of failure, and I know that there is a floor price at which the component pieces of MNKD can be offered to the highest bidder so my risk/reward ratio is good. I will continue to evaluate this over time with the only metric that matters - Cash flow - Sales versus Expenses. As long as MNKD can keep the doors open and the script growth continues, then the risk/reward ratio does not alter for me. Everything else including random presentations to investment banks is just noise. Couldn't agree more. If you are long MNKD, then you should expect at least 2 to 5 years after "launch" to see the gains we are hoping to see. Also, if you are a true long, and you are posting negative comments about MNKD and management on a public forum, you are hurting yourself and helping the shorts. In my opinion, it's ok to have bad MNKD days, but don't post your frustrations on a public forum, people read these forums just to see the moral of long investors, if there is post after post of longs bashing management, suggesting people get fired, do you think they'll buy, I don't. Im very proud of Al and Mannkind Management for all they've accomplished just getting approval, a partnership, and successfully launched Afrezza. Like I said, Afrezza is, and will continue, to change the lives of the Diabetics currently using it. Lets get behind Mannkind Management, let's show them we appreciate their hard work, and let's show some confidence in this investment. Very proud of the entire Mannkind Management team, not a pumper, just very confident. Good Luck to All MNKD Longs Forgive me, but your post is absurd. I don't want to hear from anyone what I should or should not post. I'm not a 7-year-old. I have legitimate concerns, which I had addressed directly to MNKD management and for which I have received what I consider an unsatisfactory response and continue to feel I am not being given enough information to know that my investment is or is not safe. There's nothing more to it than that. I also have done my due diligence and feel very strongly that this drug has the potential to be a blockbuster but without sufficient information that the execution is being performed competently (and I NEVER simply accept that because it's SNY doing the marketing that I should just submit to their whim), none of us has a clue. If you all want to ride your hard-earned money on promises or reputation/past experience, and not hard information, then I believe you to be nothing but reckless with your money. I don't give a damn that what I am saying is or is not fodder for shorts. I am here to satisfy only my investment. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 9, 2015 9:51:21 GMT -5
For what it's worth, there is a girl on Twitter named Melissa (@go2sleepjj) who claimed she works at SNY marketing and, based on previous posts, *seems* to be true. Who knows and if so, why she felt free to post, but I think she told the truth. Anyway, she twittered that no one wanted to work marketing for Afrezza at SNY in a Twitter 3 days ago. Intrigued, I tweeted back asking how she knows and why. She said she worked there and that the DTC was botched, thus SNY is trying to fix it with someone new doing it. She said if that new person screws up this new DTC, then it would be a negative "career changer," hence why no one wants to do it. She said SNY "was on it,"' though. If true, the bad is that SNY botched the DTC. Duh. The good is, is that SNY knows about it and is working to fix it. Anyone see that post from SA by mrcoleslaw: For what it's worth... "Sanofi rep visited w/ me this week - said Afrezza will now be marketed by people other than Sanofi reps. I asked about NRx data - although the rep didn't name numbers, the rep's facial expression said it all - and that the biggest barrier for people writing Afrezza was the PFTs that have to be performed before prescribing - this was a larger issue than most had believed it would be. Long-term will Afrezza do well? Likely, if it's affordable. I wanted to use it in a smoker who had COPD but this condition is contraindicated w/ Afrezza u" and "Toujeo was 90% the topic of conversation, followed by Apidra at 7.5% and Afrezza at 2.5%. One month the rep is touting the multiple benefits of Afrezza, the next month it's as though the medicine no longer existed. " Again, assuming this post is true, THIS situation on the ground concerns me. Are we getting the "oh by the way" sales pitch and the Junior Varsity Sales Team?!? I called and left a message with Matt asking about contract sales teams and the SNY commitment. No callback yet. And if we have a 50/50 Joint Advisory Committtee, why are we getting the scraps from the table (and why doesn't Matt know about commercials for TV, for that matter?!? Rumors of a commercial? Really?!). From what I understand from the Aug 14 CC, the contract did not require minimal sales effort numbers by SNY per standard biz practice and instead they went with the JAC. How's that working out for us?! Please no back and forth on "soft-bashing" blah blah blah. This stock is testing my patience and the criticisms IMO are very warranted. I am looking for constructive comments. Incidentally, I told Matt that no one knows about Afrezza despite the DTC. The decreasing scripts this week are another red flag. I would not be happy but could live with it if the product failed due to poor sales but had a fighting chance with good marketing and sales force support. In other words, it failed because the patients said "No" after a fair and accurate opportunity to use it was presented by their doctors. It is failing though because nobody knows about the drug! Here is the link to the tweets you are referring to: Are you Zak? PS - no one named Melissa on linkedin within 100 miles of LaJolla Ca (San Diego) who is currently or formerly with Sanofi. I seriously doubt she works or ever worked for Sanofi or any of the agencies that Sanofi uses for Afrezza. She appears to be based in San Diego and telling everyone what a successful equity trader she is (pumping some company that is 0.03/share). Sanofi is in Bridgewater NJ so their agencies(s) likely have offices in Bridgewater, Parsippany NJ, NYC or perhaps Philadelphia. Most of the major pharma agencies have interactive/digital capabilities in house. |
|
|
|
Post by newmnkdinvestor on Oct 9, 2015 10:01:41 GMT -5
For what it's worth, there is a girl on Twitter named Melissa (@go2sleepjj) who claimed she works at SNY marketing and, based on previous posts, *seems* to be true. Who knows and if so, why she felt free to post, but I think she told the truth. Anyway, she twittered that no one wanted to work marketing for Afrezza at SNY in a Twitter 3 days ago. Intrigued, I tweeted back asking how she knows and why. She said she worked there and that the DTC was botched, thus SNY is trying to fix it with someone new doing it. She said if that new person screws up this new DTC, then it would be a negative "career changer," hence why no one wants to do it. She said SNY "was on it,"' though. If true, the bad is that SNY botched the DTC. Duh. The good is, is that SNY knows about it and is working to fix it. Anyone see that post from SA by mrcoleslaw: For what it's worth... "Sanofi rep visited w/ me this week - said Afrezza will now be marketed by people other than Sanofi reps. I asked about NRx data - although the rep didn't name numbers, the rep's facial expression said it all - and that the biggest barrier for people writing Afrezza was the PFTs that have to be performed before prescribing - this was a larger issue than most had believed it would be. Long-term will Afrezza do well? Likely, if it's affordable. I wanted to use it in a smoker who had COPD but this condition is contraindicated w/ Afrezza u" and "Toujeo was 90% the topic of conversation, followed by Apidra at 7.5% and Afrezza at 2.5%. One month the rep is touting the multiple benefits of Afrezza, the next month it's as though the medicine no longer existed. " Again, assuming this post is true, THIS situation on the ground concerns me. Are we getting the "oh by the way" sales pitch and the Junior Varsity Sales Team?!? I called and left a message with Matt asking about contract sales teams and the SNY commitment. No callback yet. And if we have a 50/50 Joint Advisory Committtee, why are we getting the scraps from the table (and why doesn't Matt know about commercials for TV, for that matter?!? Rumors of a commercial? Really?!). From what I understand from the Aug 14 CC, the contract did not require minimal sales effort numbers by SNY per standard biz practice and instead they went with the JAC. How's that working out for us?! Please no back and forth on "soft-bashing" blah blah blah. This stock is testing my patience and the criticisms IMO are very warranted. I am looking for constructive comments. Incidentally, I told Matt that no one knows about Afrezza despite the DTC. The decreasing scripts this week are another red flag. I would not be happy but could live with it if the product failed due to poor sales but had a fighting chance with good marketing and sales force support. In other words, it failed because the patients said "No" after a fair and accurate opportunity to use it was presented by their doctors. It is failing though because nobody knows about the drug! There are 200 reps. Does that sounds like a a suitable sales team for the US? |
|
|
|
Post by newmnkdinvestor on Oct 9, 2015 10:04:41 GMT -5
Incidentally, I told Matt that no one knows about Afrezza despite the DTC. The decreasing scripts this week are another red flag. I would not be happy but could live with it if the product failed due to poor sales but had a fighting chance with good marketing and sales force support. In other words, it failed because the patients said "No" after a fair and accurate opportunity to use it was presented by their doctors. It is failing though because nobody knows about the drug! Here is the link to the tweets you are referring to: Are you Zak? I seriously doubt she works or ever worked for Sanofi or any of the agencies that Sanofi uses for Afrezza. She appears to be based in San Diego and telling everyone what a successful equity trader she is (pumping some company that is 0.03/share). Sanofi is in Bridgewater NJ so their agencies(s) likely have offices in Bridgewater, Parsippany NJ, NYC or perhaps Philadelphia. Most of the major pharma agencies have interactive/digital capabilities in house. yea this girl has a $1000 in her trading account. Def sounds fake and even if it isn't she sounds like a putz |
|
|
|
Post by me on Oct 9, 2015 10:14:52 GMT -5
You are exactly right. There seems to be some after the fact analysis that SNY and MNKD had planned this 'controlled marketing plan' all along, but Matt's negative comments clearly indicates that was never true. The marketing has been a debacle and frankly I have no faith that SNY and MNKD will suddenly get it right. The best he could come up with was there are 'rumors' about TV ads. At this point, I wouldn't be surprised to see either MNKD or SBY abandon the partnership in January. Recently, I googled Exubera DTC marketing and found that they faced many of the exact same issues that Afrezza has, such as the lung test issues, black box warnings and insurance coverage. It seems to me that SNY learned nothing from Pfizer's previous failure. Of course, the primary differences are the size of the delivery device,less hypos, and social media(which really wasn't around in 2007). In fact, as bad as the script numbers are, where the hell would we be if twitter wasn't around. For what it's worth, there is a girl on Twitter named Melissa (@go2sleepjj) who claimed she works at SNY marketing and, based on previous posts, *seems* to be true. Who knows and if so, why she felt free to post, but I think she told the truth. Anyway, she twittered that no one wanted to work marketing for Afrezza at SNY in a Twitter 3 days ago. Intrigued, I tweeted back asking how she knows and why. She said she worked there and that the DTC was botched, thus SNY is trying to fix it with someone new doing it. She said if that new person screws up this new DTC, then it would be a negative "career changer," hence why no one wants to do it. She said SNY "was on it,"' though. If true, the bad is that SNY botched the DTC. Duh. The good is, is that SNY knows about it and is working to fix it. Anyone see that post from SA by mrcoleslaw: For what it's worth... "Sanofi rep visited w/ me this week - said Afrezza will now be marketed by people other than Sanofi reps. I asked about NRx data - although the rep didn't name numbers, the rep's facial expression said it all - and that the biggest barrier for people writing Afrezza was the PFTs that have to be performed before prescribing - this was a larger issue than most had believed it would be. Long-term will Afrezza do well? Likely, if it's affordable. I wanted to use it in a smoker who had COPD but this condition is contraindicated w/ Afrezza u" and "Toujeo was 90% the topic of conversation, followed by Apidra at 7.5% and Afrezza at 2.5%. One month the rep is touting the multiple benefits of Afrezza, the next month it's as though the medicine no longer existed. " Again, assuming this post is true, THIS situation on the ground concerns me. Are we getting the "oh by the way" sales pitch and the Junior Varsity Sales Team?!? I called and left a message with Matt asking about contract sales teams and the SNY commitment. No callback yet. And if we have a 50/50 Joint Advisory Committtee, why are we getting the scraps from the table (and why doesn't Matt know about commercials for TV, for that matter?!? Rumors of a commercial? Really?!). From what I understand from the Aug 14 CC, the contract did not require minimal sales effort numbers by SNY per standard biz practice and instead they went with the JAC. How's that working out for us?! Please no back and forth on "soft-bashing" blah blah blah. This stock is testing my patience and the criticisms IMO are very warranted. I am looking for constructive comments. K, Kdaddy, here's about as pure and constructive a comment you'll ever get. If you believe Melissa (and why wouldn't you as you referenced her as part of your serious DD) and mrcoleslaw from SA (and why wouldn't you as your referenced him as part of your serious DD); and if you believe there is little or no SNY commitment (as indicated by the gist of your comments), then I highly recommend you dump this stock now. $3 per share is better than $0 per share. And, by keeping your $$$$$ tied up in MNKD, you're missing all the other opportunities that I'm sure you've already identified. Why wouldn't you dump the stock? Based upon your insights and beliefs, there can be no other answer for you. I'd be highly interested in exactly your reasons for being long in this stock. What positive reasons counter (<= please note, "counter", not just some random positive reasons) your negative views above? And why no mention of those reasons in your analysis? In other words, what exactly is your long thesis? Because if you can describe a long thesis that keeps you in the stock given all the calamities that you describe and imply, then I know my decision on this stock is rock solid. I'm looking forward to you sharing. If you have no cogent reasons to counter the dismal circumstances you describe above, then I guess I should probably re-evaluate my own position. Your earliest comment would be greatly appreciated. |
|
|
|
Post by dreamboatcruise on Oct 9, 2015 10:20:30 GMT -5
That's the frustrating part of this investment. Clearly an innovative treatment for millions of diabetics yet we have sales numbers of 500 after 8 months. Al, MNKD & SNY should be screaming about this product that will help save limbs & life! All we get is another presentation to hang in there..... frustrating ! As Matt even eluded to in the call... you can't stray into making medical claims that aren't on label because of FDA. His comment was in the context of social media and users being able to say things they can't. However, I too wish there were more details about plan, progress and real time corrections as things have not gone as planned. I'm having a hard time imagining that the competition is as much in the dark as investors are. They have deep pockets to figure out SNY's strategy. I do not. However, it is clear that we aren't going to get what we want with regard to information flow. |
|
|
|
Post by kbrion77 on Oct 9, 2015 10:21:35 GMT -5
If the comments from the sales rep are accurate, it is not surprising that the short interest in this stock is so massive. That's why I have been saying for the longest time the shorts know the Sanofi strategy playbook. They know there probably isn't going to be any huge announcement that would cause a squeeze or higher share price. Even if there is an insurance coverage announcement for better coverage they would still use the Sanofi lack of sales commitment to their advantage. |
|
